Fresenius stock gains as Q3 strength lifts 2026 outlook

Published on 11/04/2026 at 11:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius stock faces a stronger 2026 outlook after solid third-quarter growth. Kabi and Helios both contributed to higher operating earnings.

Strong quarter lifts Fresenius outlook

Third-quarter revenue reached EUR 5.803 billion with 5 percent organic growth.
Core EPS rose 14 percent at constant currency, supported by Kabi and Helios.
Fresenius now expects 2026 Core EPS growth in the upper half of its 10 to 15 percent range.

Fresenius, DE000FRE5EN2, Illustration mit AI erstellt.

Fresenius raised its 2026 outlook on Wednesday, November 4, after a stronger-than-expected third quarter supported by Fresenius Kabi and Fresenius Helios. In its Q3/2026 results release, the company reported group revenue of EUR 5.803 billion, up 6 percent year over year and 5 percent organically.

Group EBIT before special items reached EUR 638 million, an increase of 10 percent at constant currency. The EBIT margin expanded by 50 basis points to 11.0 percent. Core net income rose 14 percent at constant currency to EUR 403 million, while Core EPS increased 14 percent to EUR 0.72. Fresenius said the result reflected stronger operating performance and lower interest expense after continued debt reduction.

Kabi drives growth vectors

Fresenius Kabi generated revenue of EUR 2.304 billion, with organic growth of 6 percent. Its Growth Vectors - Biopharma, MedTech and Nutrition - grew 9 percent organically. Biopharma revenue increased 29 percent to EUR 296 million, while MedTech revenue rose 6 percent to EUR 428 million and Nutrition revenue advanced 4 percent to EUR 646 million.

Kabi EBIT increased 8 percent at constant currency to EUR 391 million, producing a 17.0 percent margin. The Growth Vectors contributed EUR 251 million of EBIT, up 27 percent at constant currency, and lifted their margin to 18.3 percent. Pharma remained under pressure from US pricing, with EBIT down 10 percent at constant currency to EUR 187 million.

Helios adds operating momentum

Fresenius Helios delivered organic revenue growth of 5 percent and revenue of EUR 3.405 billion. EBIT rose 19 percent at constant currency to EUR 293 million, while the margin improved to 8.6 percent. Helios Germany reported EBIT of EUR 202 million, up 25 percent, helped by cost management, solid revenue growth and a reimbursement surcharge that expired at the end of October.

Helios Spain increased EBIT 10 percent at constant currency to EUR 92 million. Fresenius also highlighted a 4.85 percent 2027 DRG inflator in Germany and a proposed emergency-care surcharge that could provide additional funding to non-university hospitals, subject to final approval.

Higher targets for fiscal 2026

Fresenius now expects constant-currency Core EPS growth in the upper half of its previous 10 to 15 percent range. The group EBIT margin indication was raised to above 11.5 percent from around 11.5 percent, while the organic revenue growth target remains 4 to 7 percent. Kabi continues to target mid- to high-single-digit organic revenue growth and a margin at the upper end of its 16.5 to 17.0 percent range. Helios continues to target mid-single-digit organic growth and a 10.0 to 10.5 percent margin.

Fresenius stock traded at 49.16 euros on Lang & Schwarz at 11:40 CET on Wednesday, November 4, 0.72 percent above the Xetra close of Tuesday, November 3. Investors can follow the real-time quote of Fresenius stock.

The next company event is the Q3 2026 webcast at 13:30 CET on Wednesday, November 4, according to the Fresenius Investor Relations page.